Abstract
Objective
Midazolam is a short-acting benzodiazepine hypnotic extensively metabolized by CYP3A4 enzyme. Orally ingested azole antimycotics, including fluconazole, interfere with the metabolism of oral midazolam during its absorption and elimination phases. We compared the effect of oral and intravenous fluconazole on the pharmacokinetics and pharmacodynamics of orally ingested midazolam.
Methods
A double-dummy, randomized, cross-over study in three phases was performed in 9 healthy volunteers. The subjects were given orally fluconazole 400 mg and intravenously saline within 60 min; orally placebo and intravenously fluconazole 400 mg; and or-ally placebo and intravenously saline. An oral dose of 7.5 mg midazolam was ingested 60 min after oral intake of fluconazole/placebo, i.e. at the end of the corresponding infusion. Plasma concentrations of midazolam, α-hydroxymidazolam and fluconazole were determined and pharmacodynamic effects were measured up to 17 h.
Results
Both oral and intravenous fluconazole significantly increased the area under the midazolam plasma concentration-time curve (AUC0-3, AUC0-17) 2- to 3-fold, the elimination half-life of midazolam 2.5-fold and its peak concentration (Cmax) 2- to 2.5-fold compared with placebo. The AUC0-3 and the Cmax of midazolam were significantly higher after oral than after intravenous administration of fluconazole. Both oral and intravenous fluconazole increased the pharmacodynamic effects of midazolam but no differences were detected between the fluconazole phases.
Conclusion
We conclude that the metabolism of orally administered midazolam was more strongly inhibited by oral than by intravenous administration of fluconazole.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allonen H, Ziegler G, Klotz U (1981) Midazolam kinetics. Clin Pharmacol Ther 30: 653–661
Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73: 658–661
Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47: 1643–1653
Gascon M-P, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41: 573–578
Hargreaves JA, Jezequel S, Houston JB (1994) Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 38: 175
Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53: 298–305
Backman J, Olkkola KT, Aranko K, Himberg J-J, Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37: 221–225
Olkkola KT, Backman J, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 55: 481–185
Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82: 511–516
Varhe A, Olkkola KT, Neuvonen PJ (1996) Effect of fluconazole dose on the extent of fluconazole triazolam interaction. Br J Clin Pharmacol, 42: 465–170
Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26: 144–160
Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488–1490
Ha HR, Rentsch KM, Kneer J, Vonderschmitt DJ (1993) Determination of midazolam and its 1-hydroxymetabolites in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit 15: 338–343
Inagaki K, Tagaki J, Lor E, Okamoto MP, Gill MA (1992) Determination of fluconazole in human serum by solid-phase extraction and reversed-phase HPLC. Ther Drug Monit 14: 306–311
Harris SC, Wallace JE, Foulds G, Rinaldi MG (1989) Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chem 33: 714–716
Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22: 947–955
Guengerich FP (1992) Characterization of human cytochrome P450 enzymes. FASEB J 6: 745–748
Kaminsky LS, Fasco MJ (1992) Small intestinal cytochromes P450. Crit Rev Toxicol 21: 407–422
Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 80: 1029–1036
Peter WHM, Kremers PG (1989) Cytochromes P450 in the intestinal mucosa of man. Biochem Pharmacol 38: 1535–1538
Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58: 492–197
Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang JD, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871–1878
Mandema JW, Tuk B, van Stevenick AL, Breimer DD, Cohen AF, Danhof M (1992) Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite oc-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51: 715–728
Park GR, Manara AR, Dawling S (1989) Extra-hepatic metabolism of midazolam. Br J Clin Pharmacol 27: 634–637
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ahonen, J., Olkkola, K.T. & Neuvonen, P.J. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 51, 415–419 (1997). https://doi.org/10.1007/s002280050223
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002280050223